Erlotinib
别名: CP358774, NSC 718781,OSI-774
中文名称:厄洛替尼,埃罗替尼
目录号:S7786 Purity: 99.99%
Erlotinib是一种EGFR抑制剂,IC50 为 2 nM,对EGFR的敏感性比对人c-Src 或 v-Ab高1000多倍。Erlotinib可诱导自噬。
CAS: 183321-74-6
客户使用Selleck的Erlotinib发表文献601篇
- Signal Transduct Target Ther, 2024 9(1):65
- Mol Cancer, 2024 23(1):48
- J Thorac Oncol, 2023 S1556-0864(23)00797-9
- Cancer Cell, 2022 40(7):754-767.e6
- Nat Biotechnol, 2022 10.1038/s41587-022-01386-z
- Immunity, 2022 55(7):1185-1199.e8
- Gastroenterology, 2022 162(4):1210-1225
- Nat Cell Biol, 2022 24(8):1291-1305
- Nature, 2021 595(7869):730-734
- Cell, 2021 184(10):2649-2664.e18
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Nat Nanotechnol, 2021 10.1038/s41565-021-00872-w
- Nat Cell Biol, 2021 23(4):377-390
- Cancer Cell, 2020 38(6):872-890.e6
- Cancer Discov, 2020 CD-19-1262
- J Thorac Oncol, 2020 15(5):752-765
- Nat Med, 2019 25(1):111-118
- Cell, 2019 178(4):807-819
- Cancer Cell, 2019 35(3):504-518
- Cancer Cell, 2019 10.1016/j.ccell.2019.09.001
- Nat Immunol, 2019 20(7):835-851
- Cancer Discov, 2019 9(6):756-777
- J Thorac Oncol, 2019 14(9):1556-1566
- Nat Med, 2018 24(11):1752-1761
- Nat Med, 2018 24(7):968-977
- Nat Med, 2018 24(4):512-517
- Nat Methods, 2018 15(8):631-639
- J Thorac Oncol, 2018 13(7):926-937
- Nat Med, 2017 23(10):1167-1175
- Nat Genet, 2017 49(12):1693-1704
- Gastroenterology, 2017 153(4):1082-1095
- Gut, 2017 66(1):124-136
- Cancer Cell, 2016 29(4):563-573
- Cancer Cell, 2015 27(3):397-408
- Cancer Cell, 2015 27(4):533-46
- Cancer Discov, 2015 5(11):1155-63
- J Thorac Oncol, 2014 9(6):775-83
- Cell Metab, 2013 17(6):1000-8
- Cancer Discov, 2013 3(12):1404-15
- Cell, 2012 151(5):937-50
- Nat Genet, 2012 44(8):852-60
- Nat Commun, 2024 15(1):2742
- Nat Commun, 2024 15(1):9473
- Cell Death Dis, 2024 15(12):912
- Cell Commun Signal, 2024 22(1):585
- Oncogene, 2024 10.1038/s41388-024-02987-5
- NPJ Precis Oncol, 2024 8(1):3
- Gastric Cancer, 2024 10.1007/s10120-024-01537-y
- Eur J Cell Biol, 2024 103(4):151457
- Mol Oncol, 2024 18(4):815-831
- Cancer Metab, 2024 12(1):37
- iScience, 2024 27(11):111133
- Int J Mol Sci, 2024 25(7)3992
- J Virol, 2024 98(7):e0058024
- Transl Oncol, 2024 39:101834
- J Biol Chem, 2024 S0021-9258(24)00139-X
- Biomedicines, 2024 12(7)1412
- Sci Rep, 2024 14(1):8200
- Transl Lung Cancer Res, 2024 13(2):321-333
- BMC Cancer, 2024 24(1):357
- World J Oncol, 2024 15(3):492-505
- STAR Protoc, 2024 5(2):103090
- World J Oncol, 2024 15(2):192-208
- Cancer Res Commun, 2024 10.1158/2767-9764.CRC-24-0221
- Nat Commun, 2023 14(1):7863
- Nat Commun, 2023 14(1):1559
- Adv Sci (Weinh), 2023 10(7):e2205262
- J Exp Clin Cancer Res, 2023 42(1):8
- J Exp Clin Cancer Res, 2023 42(1):120
- Cancer Res, 2023 83(1):141-157
- Proc Natl Acad Sci U S A, 2023 120(4):e2218118120
- NPJ Precis Oncol, 2023 7(1):12
- Breast Cancer Res, 2023 25(1):51
- Talanta, 2023 259:124553
- iScience, 2023 26(6):106820
- Int J Mol Sci, 2023 24(13)10448
- Front Pharmacol, 2023 14:1189245
- Pharmaceutics, 2023 15(4)1148
- Oncotarget, 2023 10.18632/oncotarget.28517
- Int J Oncol, 2023 62(2)20
- Cancers -Basel), 2023 15(19)4772
- FASEB J, 2023 37(11):e23223
- Exp Cell Res, 2023 430(1):113722
- Breast Cancer (Dove Med Press), 2023 10.2147/BCTT.S430513
- Braz J Med Biol Res, 2023 55:e12206
- In Vivo, 2023 37(5):1940-1950
- bioRxiv, 2023 2023.03.11.532186
- JTO Clin Res Rep, 2023 4(6):100525
- JTO Clin Res Rep, 2023 4(9):100554
- ACS Bio Med Chem Au, 2023 3(3):283-294
- Biochem Biophys Rep, 2023 34:101436
- Nat Commun, 2022 13(1):6791
- Neuro Oncol, 2022 noac105
- J Exp Clin Cancer Res, 2022 41(1):58
- Cancer Res, 2022 82(8):1534-1547
- Cancer Res, 2022 canres.2445.2021
- Cancer Res, 2022 can.21.4222
- EMBO Mol Med, 2022 14(12):e15677
- Pharmacol Res, 2022 179:106209
- Cell Death Dis, 2022 13(8):711
- Cell Death Dis, 2022 13(4):351
- J Cachexia Sarcopenia Muscle, 2022 10.1002/jcsm.12985
- Cell Rep, 2022 41(11):111827
- Br J Cancer, 2022 10.1038/s41416-022-01794-7
- Cell Commun Signal, 2022 20(1):4
- Apoptosis, 2022 10.1007/s10495-022-01751-y
- Mol Cell Proteomics, 2022 S1535-9476(22)00071-8
- Eur J Med Chem, 2022 233:114249
- Cell Oncol (Dordr), 2022 45(4):601-619
- Cell Oncol (Dordr), 2022 10.1007/s13402-022-00750-0
- Cells, 2022 11(13)2078
- Cells, 2022 11(8)1338
- iScience, 2022 25(10):105182
- Int J Mol Sci, 2022 23(15)8192
- Front Pharmacol, 2022 13:895744
- Int J Mol Sci, 2022 23(2113237)
- Front Pharmacol, 2022 13:1032975
- Cancers (Basel), 2022 14(19)4910
- Cancers (Basel), 2022 14(11)2589
- J Pers Med, 2022 12(2)258
- Ther Adv Med Oncol, 2022 14:17588359221079125
- J Biol Chem, 2022 S0021-9258(22)00469-0
- FASEB J, 2022 36(5):e22270
- Front Oncol, 2022 12:744984
- Sci Rep, 2022 12(1):8007
- Sci Rep, 2022 12(1):1626
- Sci Rep, 2022 12(1):2928
- Immunol Res, 2022 10.1007/s12026-022-09262-3
- Pharmacol Rep, 2022 10.1007/s43440-022-00396-7
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Cancer, 2022 13(15):3660-3673
- Endocr Relat Cancer, 2022 29(6):307-319
- Toxicol Appl Pharmacol, 2022 438:115911
- BMC Cancer, 2022 22(1):752
- Mol Immunol, 2022 153:135-145
- Invest New Drugs, 2022 40(2):265-273
- Clin Transl Oncol, 2022 10.1007/s12094-022-02854-3
- SLAS Discov, 2022 S2472-5552(22)12517-7
- Acta Histochem, 2022 124(4):151895
- Sci Adv, 2022 8(2):eabh3375
- Front. Drug Discov, 2022 Volume 2
- Nat Commun, 2021 12(1):4566
- Neuro Oncol, 2021 noab244
- Nat Chem Biol, 2021 10.1038/s41589-021-00947-8
- Theranostics, 2021 11(13):6632-6643
- Theranostics, 2021 11(2):824-840
- Clin Cancer Res, 2021 27(9):2533-2548
- Cancer Res, 2021 canres.1112.2021
- Proc Natl Acad Sci U S A, 2021 118(19)e2019580118
- PLoS Biol, 2021 19(6):e3000797
- Cancer Lett, 2021 507:40-54
- Pharmacol Res, 2021 170:105701
- Pharmacol Res, 2021 169:105685
- Cell Rep, 2021 37(1):109774
- Cell Rep, 2021 37(8):110054
- Cell Rep, 2021 37(11):110096
- Mol Ther Nucleic Acids, 2021 26:798-812
- Cell Rep, 2021 35(11):109233
- NPJ Precis Oncol, 2021 5(1):65
- J Cell Biol, 2021 220(2)e202004229
- J Transl Med, 2021 19(1):91
- PLoS Pathog, 2021 17(1):e1009216
- Cell Oncol (Dordr), 2021 10.1007/s13402-021-00632-x
- Cells, 2021 10(4)716
- Commun Biol, 2021 4(1):1237
- Commun Biol, 2021 4(1):834
- Mol Ther Oncolytics, 2021 20:364-372
- Cancer Sci, 2021 112(5):1853-1864
- Front Pharmacol, 2021 12:764699
- Front Cell Dev Biol, 2021 9:634371
- J Virol, 2021 JVI0119521
- Lung Cancer, 2021 162:79-85
- J Cell Mol Med, 2021 10.1111/jcmm.16555
- Cancers (Basel), 2021 13(18)4651
- Cancers (Basel), 2021 13(14)3635
- Cancers (Basel), 2021 13(16)3938
- Cancers (Basel), 2021 13(6)1198
- Front Oncol, 2021 11:665045
- Front Oncol, 2021 11:750852
- Front Oncol, 2021 11:754146
- Front Oncol, 2021 11:711043
- Front Oncol, 2021 11:686445
- Ann Transl Med, 2021 9(18):1455
- Cancer Res Treat, 2021 10.4143/crt.2021.385
- Sci Rep, 2021 11(1):23302
- Sci Rep, 2021 11(1):7259
- Environ Toxicol, 2021 10.1002/tox.23125
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Transl Lung Cancer Res, 2021 10(9):3737-3744
- Onco Targets Ther, 2021 14:3813-3820
- J Cell Sci, 2021 134(19)jcs258409
- Drug Metab Dispos, 2021 49(1):53-61
- Oncol Lett, 2021 21(1):44
- Exp Ther Med, 2021 21(1):9
- Anticancer Res, 2021 41(3):1261-1269
- Sci Adv, 2021 7(10)eabe8671
- Pharmazie, 2021 76(12):602-605
- Transl Cancer Res, 2021 10(2):1025-1033
- Nat Commun, 2020 10;11(1):2935
- Nat Commun, 2020 11(1):3521
- Nat Commun, 2020 11(1):3157
- J Am Soc Nephrol, 2020 ASN.2019111215
- Acta Neuropathol, 2020 10.1007/s00401-020-02226-7
- Redox Biol, 2020 36:101652
- EMBO J, 2020 2;39(5):e101679
- Cancer Res, 2020 80(22):4998-5010
- EMBO Mol Med, 2020 e11099
- EMBO Mol Med, 2020 12(8):e11987
- Cancer Lett, 2020 477:19-30
- Cancer Lett, 2020 476:23-33
- Cell Rep, 2020 31(11):107764
- Mucosal Immunol, 2020 4
- Oncogene, 2020 39(20):3997-4013
- Oncogene, 2020 10.1038/s41388-020-01497-4
- Transl Res, 2020 S1931-5244(20)30257-7
- Elife, 2020 2;9:e54954
- Sci Signal, 2020 28;13(629)
- Neurobiol Dis, 2020 9;104961
- Chin Med J (Engl), 2020 5;133(11):1304-1311
- Cells, 2020 9(4)E1003
- Biochem Pharmacol, 2020 10.1016/j.bcp.2020.113914
- Biochem Pharmacol, 2020 114154
- Mol Cancer Ther, 2020 5;molcanther.510.2019
- Mol Cancer Ther, 2020 5 pii: molcanther
- Mol Cancer Ther, 2020 19(7):1562-1571
- Mol Cancer Ther, 2020 molcanther.1160.2019
- Cancer Sci, 2020 111(10):3793-3801
- Int J Mol Sci, 2020
- J Cell Physiol, 2020 10.1002/jcp.29463
- Int J Mol Sci, 2020 21(23)E9307
- Front Cell Dev Biol, 2020
- Cancers (Basel), 2020 12(11)E3172
- Cancers (Basel), 2020 10;12(1) pii: E173
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-20-0420
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Cancers (Basel), 2020 13;12(2) pii: E436
- Cancers (Basel), 2020 12(2)
- Cancers (Basel), 2020 12(1)
- Eur J Pharm Biopharm, 2020 S0939-6411(20)30305-2
- Chin Med, 2020 15:66
- J Biol Chem, 2020 jbc.RA120.014960
- Front Oncol, 2020 12;10:696
- Front Oncol, 2020 10:585292
- Front Oncol, 2020 10:1593
- Sci Rep, 2020 10(1):17768
- Sci Rep, 2020 17;10(1):2735
- Sci Rep, 2020 10(1):3842
- Sci Rep, 2020 10(1):4748
- Cancer Res Treat, 2020 10.4143/crt.2020.585
- Environ Toxicol, 2020 10.1002/tox.22942
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 44(6):2581-2594
- Oncol Rep, 2020 45(1):217-229
- J Cell Commun Signal, 2020 10.1007
- Onco Targets Ther, 2020 13:10983-10994
- Transl Lung Cancer Res, 2020 9(5):1904-1914
- J Cancer, 2020 11(19):5746-5757
- Radiat Oncol, 2020 15(1):58
- J Pharm Biomed Anal, 2020 195:113864
- Cancer Manag Res, 2020 12:4453-4460
- Cancer Manag Res, 2020 12:4283-4297
- Thorac Cancer, 2020 11(8):2101-2111
- J Pharmacol Toxicol Methods, 2020 106895
- Transl Cancer Res, 2020 9(4):2542-2555
- Neurooncol Adv, 2020 2(1):vdaa067
- Cancer Drug Resist, 2020 3(3):603-612
- Cancer Drug Resist, 2020 3(4):980-991
- Nat Commun, 2019 10(1):2532
- Autophagy, 2019 10.1080/15548627.2019.1659654
- Small, 2019 15(33):e1900309
- Clin Cancer Res, 2019 25(11):3341-3351
- Clin Cancer Res, 2019 10.1158/1078-0432
- J Exp Clin Cancer Res, 2019 38(1):84
- J Exp Clin Cancer Res, 2019 38(1):154
- J Exp Clin Cancer Res, 2019 38(1):83
- J Exp Clin Cancer Res, 2019 38(1):211
- Cancer Res, 2019 79(11):2947-2961
- Cancer Res, 2019 79(19):5048-5059
- Nano Lett, 2019 19(10):7526-7533
- Mol Syst Biol, 2019 15(3):e8323
- Cancer Lett, 2019 466:23-34
- Cancer Lett, 2019 454:78-89
- Cell Syst, 2019 10.1016/j.cels.2019.10.002
- Cell Death Dis, 2019 10(4):282
- Cell Rep, 2019 28(8):2012-2022
- Cell Rep, 2019 28(2):512-525.e6
- Cell Chem Biol, 2019 26(3):400-410
- JCI Insight, 2019 4(4)
- Oncogene, 2019 38(5):656-670
- JCI Insight, 2019 4(21)
- Anal Chem, 2019 91(15):10026-10032
- Breast Cancer Res, 2019 21(1):77
- Int J Cancer, 2019 10.1002/ijc.32487
- Oncogenesis, 2019 8(12-:70
- Artif Cells Nanomed Biotechnol, 2019 47(1):3231-3238
- Cancer Cell Int, 2019 19:10
- Biochem Pharmacol, 2019 169:113640
- Int J Mol Sci, 2019 20(19)
- Int J Mol Sci, 2019 20(10)
- Int J Mol Sci, 2019 20(18)
- J Ethnopharmacol, 2019 239:111928
- Respir Res, 2019 20(1-:270
- Am J Cancer Res, 2019 9(12):2719-2729
- Am J Cancer Res, 2019 9(8):1708-1721
- Cancers (Basel), 2019 11(6)
- Int J Oncol, 2019 54(2):527-536
- Cancers (Basel), 2019 11(1)
- Eur J Pharmacol, 2019 850:97-108
- Transl Oncol, 2019 12(3):432-440
- J Biol Chem, 2019 294(27):10530-10543
- Front Oncol, 2019 9:586
- Front Oncol, 2019 9:461
- Front Oncol, 2019 9:1070
- Sci Rep, 2019
- Sci Rep, 2019 9(1):845
- Sci Rep, 2019 9(1):5309
- Sci Rep, 2019 9(1):5692
- Cytotherapy, 2019 21(6):603-611
- Oncol Rep, 2019 41(1):447-454
- Biosci Rep, 2019 39(8)
- J Cancer, 2019 10(9):2063-2073
- PLoS One, 2019 14(9):e0214901
- Mol Pharmacol, 2019 95(5):528-536
- Cancer Biol Ther, 2019 10.1080/15384047.2019.1665952
- Gene, 2019 687:143-150
- Biochem Biophys Res Commun, 2019 513(3):546-552
- Endocr Connect, 2019 8(6):680-690
- Oncol Lett, 2019 17(3):2729-2736
- FEBS Open Bio, 2019 9(10):1689-1704
- Anticancer Res, 2019 39(7):3785-3793
- Clin Respir J, 2019 13(1):23-33
- Transl Cancer Res, 2019 8(6):2425-2438
- Nat Commun, 2018 13;9(1):2720
- Nat Commun, 2018 9(1):4655
- Cancer Commun (Lond), 2018 38(1):19
- J Clin Invest, 2018 128(6):2500-2518
- J Exp Med, 2018 215(1):115-140
- Clin Cancer Res, 2018 24(23):6066-6077
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-0792
- Clin Cancer Res, 2018 24(11):2594-2604
- Clin Cancer Res, 2018 24(13):3126-3136
- Cancer Res, 2018 78(24):6866-6880
- Cancer Res, 2018 78(16):4642-4657
- EMBO Mol Med, 2018 10(9)
- Proc Natl Acad Sci U S A, 2018 115(26):E6030-E6038
- Cancer Immunol Res, 2018 10.1158/2326-6066
- PLoS Biol, 2018 16(12):e2006660
- PLoS Biol, 2018
- Cell Death Dis, 2018 9(3):262
- Cell Death Dis, 2018
- Mol Ther Nucleic Acids, 2018 11:455-467
- JCI Insight, 2018 3(24)
- Sci Signal, 2018 11(549)
- Int J Cancer, 2018 143(8):1994-2007
- Mol Cancer Ther, 2018 17(10):2217-2225
- Mol Cancer Ther, 2018 17(4):806-813
- J Cell Physiol, 2018 233(9):6975-6983
- Front Pharmacol, 2018 9:1214
- J Virol, 2018
- Oncotarget, 2018 9(100):37352-37366
- Oncotarget, 2018 9(60):31572-31589
- Oncotarget, 2018 9(51):29680-29697
- Oncotarget, 2018 9(101):37520-37533
- J Cell Mol Med, 2018 22(6):3073-3085
- Lung Cancer, 2018 126:72-79
- Mol Cancer Res, 2018 16(5):777-790
- Int J Oncol, 2018
- Mol Cancer Res, 2018 16(11):1773-1784
- Mol Cancer Res, 2018 16(7):1185-1195
- Mol Pharm, 2018 15(5):1892-1900
- J Biol Chem, 2018 293(35):13401-13414
- Sci Rep, 2018 8(1):18043
- Molecules, 2018 23(7)1797
- J Immunol, 2018 200(8):2809-2818
- J Proteome Res, 2018 17(1):63-75
- Pigment Cell Melanoma Res, 2018 31(2):253-266
- Oncol Rep, 2018 40(1):29-38
- Cancer Med, 2018 7(4):1394-1403
- Cancer Med, 2018
- Endocr Relat Cancer, 2018 25(4):471-480
- BMC Cancer, 2018
- Toxicol Sci, 2018 166(2):394-408
- J Pharm Biomed Anal, 2018 150:112-120
- Cancer Manag Res, 2018 10:565-581
- J Craniomaxillofac Surg, 2018 46(3):492-497
- Biochem Biophys Res Commun, 2018 495(1):733-739
- Oncol Lett, 2018 15(5):6107-6114
- Acta Haematol, 2018 140(1):30-39
- Urology, 2018 112:225.e1-225.e7
- Anticancer Res, 2018 38(11):6195-6200
- F1000Res, 2018 7:1906
- Oncoscience, 2018 5(1-2):21-38
- Sci Transl Med, 2017 14;9(394):eaah6144
- Nat Commun, 2017 8(1):410
- Nat Commun, 2017 8(1):823
- Biomaterials, 2017 148:69-80
- Genome Med, 2017 9(1):40
- Clin Cancer Res, 2017 23(19):5923-5935
- Cancer Res, 2017 77(8):2018-2028
- Genes Dev, 2017 31(2):184-196
- Cell Death Dis, 2017 8(8):e2980
- Cell Death Dis, 2017 8(5):e2773
- Oncogene, 2017 36(48):6691-6700
- Phytomedicine, 2017
- Elife, 2017 6
- Elife, 2017 6e27388
- Biomed Pharmacother, 2017 96:619-625
- Cell Biosci, 2017 7:43
- Mol Oncol, 2017 11(6):628-639
- Mol Oncol, 2017 11(8):1065-1077
- Arch Toxicol, 2017 91(8):2921-2938
- Cancer Sci, 2017
- Mol Cancer Ther, 2017
- Mol Cancer Ther, 2017 16(10):2234-2245
- J Am Heart Assoc, 2017 6(10)
- Oncotarget, 2017 8(35):58417-58429
- Oncotarget, 2017 8(58):98771-98781
- Oncotarget, 2017 8(14):22414-22432
- Oncotarget, 2017 8(40):68221-68229
- Oncotarget, 2017 9(9):8206-8222
- Oncotarget, 2017 8(29):47305-47316
- Oncotarget, 2017
- Oncotarget, 2017
- Oncotarget, 2017 9(2):1641-1655
- Lung Cancer, 2017 106:115-124
- Lung Cancer, 2017 113:72-78
- Mol Cell Biol, 2017 37(10)e00649-16
- Int J Oncol, 2017 50(6):2049-2058
- Gels, 2017 3(3)
- Sci Rep, 2017
- Sci Rep, 2017 7(1):16763
- JCO Precis Oncol, 2017 1:PO.16.00019
- Sci Rep, 2017 7(1):781
- Sci Rep, 2017 7(1):1669
- Sci Rep, 2017 7:44206
- Cancer Res Treat, 2017 49(4):915-926
- J Proteome Res, 2017 16(2):1077-1086
- Oncol Rep, 2017 38(4):2205-2210
- Biosci Rep, 2017 37(3)
- BMC Cancer, 2017
- PLoS One, 2017 12(9):e0184155
- PLoS One, 2017 12(2):e0172599
- PLoS ONE, 2017
- Clin Lung Cancer, 2017
- J Appl Toxicol, 2017 37(3):382-390
- Biochem Biophys Res Commun, 2017 486(4):1027-1033
- SLAS Discov, 2017 22(7):915-922
- Pancreas, 2017 46(4):575-581
- J Biomed Nanotechnol, 2017 13(4):458-68
- Biol Pharm Bull, 2017 40(8):1306-1313
- Tumour Biol, 2017 39(7):1010428317709639
- Nat Commun, 2016 7:11815
- Nat Commun, 2016 7:11551
- Genome Biol, 2016 17:80
- Proc Natl Acad Sci U S A, 2016 113(21):E2935-44
- Cancer Immunol Res, 2016
- Cancer Lett, 2016 376(1):188-96
- Cell Death Dis, 2016
- J Pathol, 2016 239(3):320-34
- PLoS Pathog, 2016
- PLoS Pathog, 2016 12(5):e1005622
- Mol Cancer Ther, 2016
- Cancer Sci, 2016 107(8):1134-40
- Oncotarget, 2016 7(30):47998-48010
- Oncotarget, 2016 7(13):15492-506
- Oncotarget, 2016 7(32):51922-51933
- Oncotarget, 2016 7(37):59809-59819
- Oncotarget, 2016 7(4):3847-56
- Oncotarget, 2016
- Oncotarget, 2016 7(18-:25983-6002
- Int J Oncol, 2016 49(1):243-52
- Int J Oncol, 2016 48(6):2558-66
- Eur J Pharmacol, 2016 789:458-467
- Neoplasia, 2016 18(7):425-35
- Neoplasia, 2016 18(2):111-20
- Biochim Biophys Acta, 2016 1859(11):1449-1458
- BMC Genomics, 2016 17(1):723
- Stem Cells Int, 2016 2016:9601493
- Exp Cell Res, 2016 344(2):194-200
- PLoS ONE, 2016
- PLoS One, 2016 11(5):e0155230
- PLoS One, 2016 11(6):e0158617
- BMC Vet Res, 2016 12:82
- Mol Cell, 2015 57(3):521-36
- Cell Death Differ, 2015 22(5):801-14
- Clin Cancer Res, 2015 21(20):4686-97
- Cancer Res, 2015 10.1158/0008-5472.CAN-14-2005
- Proc Natl Acad Sci USA, 2015 112(6):1839-44
- Proc Natl Acad Sci U S A, 2015 112(30):9406-11
- Cell Rep, 2015 11(1):98-110
- Cell Commun Signal, 2015 13:26
- Acta Pharmacol Sin, 2015 10.1038/aps.2015.4
- Oncogene, 2015
- Elife, 2015
- Int J Cancer, 2015 10.1002/ijc.29483
- Biochem Pharmacol, 2015 98(4):639-48
- Radiother Oncol, 2015 116(3):431-7
- Mol Cancer Ther, 2015 10.1158/1535-7163.MCT-13-0951
- J Virol, 2015 90(4):1918-30
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015 6(7):5118-33
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015 6(16):14329-43
- Oncotarget, 2015
- Am J Physiol Heart Circ Physiol, 2015 309(9):H1516-27
- FASEB J, 2015 29(9):3702-12
- Drug Des Devel Ther, 2015 9:3183-90
- J Biol Chem, 2015
- J Biol Chem, 2015 290(28):17495-504
- Ann Thorac Surg, 2015 100(2):414-21
- Sci Rep, 2015
- Sci Rep, 2015
- Biochem J, 2015 471(2):267-79
- J Chromatogr A, 2015 1400:117-23
- J Biotechnol, 2015 10.1016/j.jbiotec.2015.01.012
- Biochem J, 2015 465(2):271-9
- Toxicol Appl Pharmacol, 2015 10.1016/j.taap.2015.05.001
- PLoS One, 2015 10(5):e0127348
- PLoS One, 2015 10(10):e0140782
- PLoS One, 2015 10(2):e0118210
- PLoS One, 2015 10(4):e0123901
- Cancer Prev Res (Phila), 2015 8(9):765-76
- Biochem Biophys Res Commun, 2015 463(4):612-7
- Cancer Chemoth Pharm, 2015 10.1007/s00280-015-2751-6
- Anal Biochem, 2015 10.1016/j.ab.2015.01.016
- Oncol Lett, 2015
- Prostate, 2015 10.1002/pros.22945
- Pathol Oncol Res, 2015 10.1007/s12253-015-9916-9
- Biomarkers, 2015
- Tumour Biol, 2015 36(7):5485-95
- BMC Res Notes, 2015 8:203
- Nat Commun, 2014 3.84166666666667
- Clin Cancer Res, 2014 20(15):4047-58
- Clin Cancer Res, 2014 20(18):4806-15
- Clin Cancer Res, 2014 20(13):3613-22
- Cancer Res, 2014 74(1):253-62
- J Natl Cancer Inst, 2014 106(9)
- Cell Death Dis, 2014 5:e1445
- Oncogene, 2014 33(35):4418-23
- Elife, 2014 3:e02523
- J Transl Med, 2014 12(1):265
- Anal Chem, 2014 86(21):10568-75
- Br J Pharmacol, 2014 171(24):5757-73
- Antioxid Redox Sign, 2014 10.1089/ars.2013.5304
- Mol Oncol, 2014 10.1016/j.molonc.2014.05.005
- Lung Cancer, 2014 85(2):152-60
- Antimicrob Agents Chemother, 2014 10.1128/AAC.02393-14
- BMC Microbiol, 2014
- Drug Metab Dispos, 2014 42(11):1851-7
- PLoS One, 2014 9(12):e114000
- Biomed Res Int, 2014
- J Mol Endocrinol, 2014 52(2):223-34
- J Pharmacol Exp Ther, 2014 351(2):352-8
- Oncol Res, 2014 21(3):137-44
- Histochem Cell Biol, 2014 10.1007/s00418-014-1223-0
- Am J Transl Res, 2014 6(6):649-63
- Biores Open Access, 2014 3(4):176-82
- Nat Chem Biol, 2013 9(5):307-12
- Cell Rep, 2013 4(4):764-75
- BRIT J CANCER, 2013 109(8):2155-66
- Sci Signal, 2013
- Int J Cancer, 2013 133(2):505-13
- Mol Cancer Ther, 2013 12 (10): 2213–2225.
- Mol Cancer Ther, 2013 12(10):2213-25
- Oncotarget, 2013
- Lung Cancer, 2013 81(3):354-61
- Invest Ophthalmol Vis Sci, 2013 54(1):864-70
- PLoS One, 2013 8(1):e54509
- PLoS One, 2013 8(12):e81393
- PLoS One, 2013 8(12):e82236
- PLoS One, 2013 8(5):e62104
- Head Neck, 2013 35(1):86-93
- Prostate, 2013 73(13):1453-61
- Laser in Surg Med, 2013 45(7):460-8
- Tuberc Respir Dis, 2013 75(1):9-17
- Tuberc Respir Dis, 2013 75(3):95-103
- J Clin Invest, 2012 122(9):3197-210
- Int J Cancer, 2012 131(12):2961-9
- Int J Cancer, 2012 131(2):334-43
- Cancer, 2012 118(21):5198-209
- Cancer Sci, 2012 103(1):7-16
- Int J Mol Sci, 2012 13(9):12000-16
- PLoS One, 2012 7(9):e42441
- PLoS One, 2012 7(10):e48532
- Clin Cancer Res, 2011 17(8):2260-9
- Oncogene, 2011 30(22):2547-57
- Mol Cancer Ther, 2011 10(10):1846-56
- Transl Oncol, 2011 4(2):92-100
- J Immunother, 2011 34(4):372-81
- Int J Proteomics, 2011 2011:215496
- Carcinogenesis, 2010 31(4):577-86
- Carcinogenesis, 2010 31(11):1948-55
- Case Western Reserve University, 2010 Zhang Z
- Eur J Pharm Sci, 10.1016/j.ejps.2016.04.025
化学信息&溶解度
分子量 | 393.44 |
分子式 | C22H23N3O4 |
CAS号 | 183321-74-6 |
Smiles | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 254.16 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 11 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 254.16 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 15 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
30%PEG300
5%Tween80
60%ddH2O
浓度:3mg/ml
(7.63mM)
操作示例:以 1 mL 工作液为例,取50μL60mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入600μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5% DMSO
95% corn oil
浓度:0.55mg/ml
(1.40mM)
操作示例:以1 mL工作液为例,取50μL 11mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。